CLINICAL_TRIALS
trial_result
· 2019-08-02
Clinical Trial Update: Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF [Phase 3]
Summary
Phase 3 trial of Sexelaxin added to standard therapy in acute heart failure was terminated; results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Acute Heart Failure | Phase 3 | Status: TERMINATED | Results posted: 2019-08-02